Treatment type may predict the risk of relapse during pregnancy in women with relapsing-remitting multiple sclerosis (RRMS), researchers say.
Historically, RRMS disease activity has been known to decrease during pregnancy. However, the interaction between disease activity and pregnancy in the era of modern therapy, including high-efficacy disease-modifying therapy (DMT), is unclear.